220 participants
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-28
- Start Date:
- 2020-12-18
- Completion:
- 2025-07-03
Conditions
- Urinary Bladder Neoplasms
Interventions
- DRUG
- BIOLOGICAL